Release Date: 28/01/11 14:29 Summary: Quarterly Activities Report to 31 December 2010 Price Sensitive: Yes Download Document 110.68KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%